<DOC>
	<DOC>NCT00426140</DOC>
	<brief_summary>The main purpose of this study is to characterize the distribution, metabolism, and elimination (ADME) of Patupilone after a single intravenous administration in patients with advanced solid tumor malignancies</brief_summary>
	<brief_title>Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>1. 18 years or older 2. World Health Organization (WHO) Performance Status Score of: 0 you are fully active and more or less as you were before your illness, 1 you cannot carry out heavy physical work, but can do anything else. 3. Adequate hematological laboratory parameters 4. No major impairment of renal or hepatic function 5. Female patients must have a negative serum pregnancy test at screening. 1. Severe and/or uncontrolled medical disease; 2. Severe cardiac insufficiency with uncontrolled and/or unstable cardiac or coronary artery disease; 3. Known diagnosis of human immunodeficiency virus (HIV) infection; 4. Presence of any other active or suspected acute or chronic uncontrolled infection; 5. Symptomatic brain metastases or leptomeningeal disease. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>EPO</keyword>
	<keyword>Patupilone</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>